Clinical Trial Detail

NCT ID NCT02269943
Title Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications

nasopharynx carcinoma

Therapies

Azacitidine

Age Groups: adult

No variant requirements are available.